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Purpose: Monte Carlo (MC) codes are widely used in the 
hadrontherapy community due to their detailed description 
of radiation transport and interaction with matter. In this 
work, we present the latest developments and applications 
of the FLUKA Monte Carlo code [1,2].   
Material/methods: MC methods are being utilized at several 
institutions for a wide range of activities spanning from beam 
characterization to quality assurance and 
dosimetric/radiobiological studies. The suitability of a MC 
code for application to hadrontherapy demands accurate and 
reliable physical models for the description of the transport 
and the interaction of all components of the expected 
radiation field. This becomes extremely important to 
correctly perform not only physical but also biological dose 
calculations. In addition, accurate prediction of emerging 
secondary radiation is of utmost importance in emerging 
areas of research aiming at in-vivo treatment verification.  
Results: Validations and applications at several experimental 
sites as well as proton/ion therapy facilities with active beam 
delivery systems will be presented:  
• Physical database generation: laterally integrated 
depth-dose profiles, lateral-dose distributions at 
different depths, secondary fragment yields and 
fragment energy spectra at different depths.  
• Forward MC re-calculations of physical/RBE-
weighted dose distributions of proton and carbon 
ion treatment plans.  
• MC-based treatment planning for proton and heavy 
ions beam therapy. 
• Studies for introducing new ions (4He and 16O) in 
the clinical practice.  
Conclusions: FLUKA's flexibility and the satisfactory 
agreements with several dosimetric data and nuclear 
fragment yields demonstrate that the code is a valuable and 
powerful support for the hadrontherapy community.  
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Purpose: Conventionally, intensity modulated particle 
therapy (IMPT) fields are optimized independently of the 
fractionation scheme. Following some precursory works [1—
3], this study aims at investigating whether the application of 
spatial and temporal modulations in fractionation patterns, 
which involve the delivery of daily inhomogeneous fractional 
dose (IFD) distributions, may increase the therapeutic gain. 
Materials/Methods: We simulated the irradiation of different 
clinical cases with different ions (1H, 4He, 12C) and we carried 
out a comparison between two types of treatment plans. 
These were: (1) a conventional plan with a standard 
fractionation scheme in which each beam irradiates the 
whole planning target volume (PTV) delivering a uniform dose 
of 2 Gy per fraction; (2) an alternative plan that implies IFD 
distributions, delivering homogeneous dose to distinct regions 
of the PTV in different fractions. Each field was weighted to 
minimize its contribution to the proximal region of the PTV, 
so to limit the dose excursion in the surrounding normal 
tissues and obtain different local fractionation schemes in 
the volumes of interest. The comparison was based on the 
evaluation of the tumor complication probability (TCP) and 
normal tissue complication probability (NTCP). We evaluated 
these quantities following the approach proposed by Kallman 
et al. [4], based on the Linear-Quadratic-Poisson model. We 
considered a variable relative biological effectiveness (RBE) 
and the impact of the variable linear energy transfer (LET) 
distributions on the sensitivity to the time structure of the 
irradiation. 
Results: For the considered cases, the comparison showed 
that the IFD-based approach leads to an improvement of the 
therapeutic index with respect to the standard approach (+6-
10%). The extent of the gain is dependent, among other 
factors, on the sensitivity of the tissues to the employed ion 
radiation. Some critical issues were identified related to the 
choice of weights and spatial configurations of the fields. 
Conclusions: This work investigates the possibility to improve 
the therapeutic index by delivering temporally and spatially 
heterogeneous dose distributions in the PTV, following the 
IFD paradigm. A methodology has been found which has 
proven to be successful in the considered clinical cases. 
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In Particle Therapy, cancer treatments are performed using 
accelerated charged particles whose high irradiation 
precision and conformity allows the tumor destruction while 
sparing the surrounding healthy tissues. Dose release 
monitoring devices using photons and charged particles 
produced by the beam interaction with the patient body have 
already been proposed, but no attempt based on the 
detection of the abundant secondary radiation neutron 
component has been made yet. The reduced attenuation 
length of neutrons yields a secondary particle sample that is 
larger in number when compared to photons and charged 
particles. Furthermore, neutrons allow for a backtracking of 
the emission point that is not affected by multiple scattering. 
Since neutrons can release a significant dose far away from 
the tumor region, a precise measurement of their flux, 
production energy and angle distributions is eagerly needed 
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in order to improve the Treatment Planning Systems (TPS) 
software, so to properly take into account not only the 
normal tissue toxicity in the target region, but also the risk 
of late complications in the whole body [1,2]. All the 
aforementioned issues underline the importance for an 
experimental effort devoted to the precise characterization 
of the neutron production gaining experimental access both 
to the emission point and production energy.  
The technical challenges posed by a neutron detector aiming 
for high detection efficiency and good backtracking precision 
will be addressed within the MONDO (MOnitor for Neutron 
Dose in hadrOntherapy) project. The MONDO main goal is to 
develop a tracking detector targeting fast and ultrafast 
secondary neutrons. 
The main interaction mechanism of fast and ultrafast 
neutrons in plastic scintillators is the elastic scattering with 
hydrogen nuclei. In case of double elastic scattering events, 
if both protons recoil are measured, the neutron energy and 
direction can be reconstructed. The tracking and energy 
resolution achievable on the two recoiling protons drive the 
neutron energy and angular resolutions. The tracker is than 
composed by matrix (10 x 10 x 20 cm3) of squared 
scintillating fiber of 0.250 mm). The fibers are used at the 
same time as target for the elastic n-p scattering of the 
impinging neutrons and as active detector for the recoiling 
protons. The light produced and collected in the fibers will 
be amplified using a triple GEM [3] and acquired using CMOS 
Single Photon Avalanche Diode arrays [4]. 
 
The neutron tracker will measure the neutron production 
yields, as a function of production angle and energy, using 
different therapeutical beams (protons, 12C ions and possibly 
4He and 16O ions).  
The MONDO project and the preliminary test of the different 
components will be presented. 
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Purpose: A growing body of evidence on cancer stem cells 
(CSC) relates their presence in tumours to poor treatment 
outcome. Symmetrical division of CSC during therapy is a key 
factor that contributes to repopulation and treatment 
failure. However, the literature lacks quantification of the 
CSC fraction and their division pattern. Head and neck 
cancers (HNC) are challenging due to high hypoxic content 
and repopulation ability by CSCs. The aim of this work was to 
quantify the symmetrical division of CSC in a hypoxic HNC 
model treated with hyperfractionated radiotherapy and 
assess tumour response as a function of the interplay 
between CSC and the hypoxic fraction.  
Methods: A Monte Carlo technique was employed to grow a 
HNC consisting of CSC, differentiated and quiescent cells. For 
a biologically realistic growth, the initial symmetrical division 
probability of CSC was 1.9%, leading to a pre-treatment CSC 
population of 5.9%. The model considers various hypoxia 
levels as a function of the mean partial oxygen tension, from 
3mmHg to 10mmHg. CSC radioresistance was established 
according to literature [1] and adapted for HNC. 
Results: Initial CSC fraction changes during treatment due to 
repopulation, radioresistance and hypoxia. Figure 1 shows 
the variation of CSC fraction during therapy for three hypoxic 
scenarios. The figure shows that in mildly hypoxic tumours (9 
mmHg) the fraction of CSCs during treatment overtakes the 
fraction of CSC in severely hypoxic ones (3 mmHg). It nearly 
appears that hypoxia keeps the CSC subpopulation under 
control. This behaviour is due to the fact that in well-
oxygenated tumors CSCs are the most resistant subpopulation 
and they outlive non-stem cells, while in hypoxic tumors 
there are hypoxic resistant subpopulations as well as CSCs, 
thus the hypoxic content and CSC fraction are intertwined. 
 
 
While hyperfractionation (1.2Gy in 70 fractions) is likely to 
be the most optimal radiotherapy schedule for advanced HNC 
[2] the model shows that if repopulation occurs via 
symmetrical division of CSCs with a probability greater than 
5%, radiotherapy as a sole agent is not efficient for hypoxic 
HNC (table 1). However, oxic HNC benefit from 
hyperfractionation even for larger probabilities of 
symmetrical division, thus an overall dose of 84Gy in two 
1.2Gy daily fractions is effective to overcome repopulation. 
Conclusions: Quantitative evaluation of CSCs and hypoxia are 
crucial for designing successful treatment regimens for 
resistant subpopulations. 
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Purpose: Despite recent advancements in radiotherapy and 
radiosurgery, significant limitations remain. Hadrontherapy, 
which has been in clinical use for more than 15 years, has 
shown remarkable effectiveness. However, it still could 
benefit from a lower impact on non-targeted tissues to allow 
its administration at higher doses. This is the reason why we 
propose a new approached called hadron minibeam radiation 
